Skip to main content

Table 3 Association between type of treatment and clinical variables

From: Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis

Clinical variables

ICIs

CHTs

n

p-value*

SARS-CoV2 IgG/IgM

 IgG and/or IgM+

9

39

885

0.04

 IgG and IgM−

278

559

Gender

 Male

154

207

885

< 0.001

 Female

133

391

Age (years)

 < 70

194

416

885

n.s

 ≥ 70

93

182

Cancer stage

 I–III

38

97

804

0.05

 IV

249

420

ECOG performance status

 0

244

265

793

< 0.001

 1–4

41

243

Lymphopenia

 Yes

2

90

755

< 0.001

 No

256

407

Leukopenia

 Yes

0

91

764

< 0.001

 No

258

415

  1. ICIs Immune Checkpoint Inhibitors Treatment, CHTs chemotherapy treatments, n number of patients, n.s not statistically significant
  2. *The p-values represent χ2 tests of independence indicating associations between type of treatment and categorical clinical variables (statistically significant p < 0.05)